DSIP vs Tirzepatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
DSIP
Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.
Full details →Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →Side-by-Side Comparison
| Aspect | DSIP | Tirzepatide |
|---|---|---|
| Mechanism | Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties. | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. |
| Typical Dosage | Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically. | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. |
| Administration | Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use. | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. |
| Side Effects | May cause grogginess upon waking, vivid dreams, or temporary headaches. | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. |
| Best For |